376 related articles for article (PubMed ID: 18511846)
41. RAGE and cardiovascular disease.
Park S; Yoon SJ; Tae HJ; Shim CY
Front Biosci (Landmark Ed); 2011 Jan; 16(2):486-97. PubMed ID: 21196183
[TBL] [Abstract][Full Text] [Related]
42. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
43.
López-Díez R; Shen X; Daffu G; Khursheed M; Hu J; Song F; Rosario R; Xu Y; Li Q; Xi X; Zou YS; Li H; Schmidt AM; Yan SF
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1536-1547. PubMed ID: 28642238
[TBL] [Abstract][Full Text] [Related]
44. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.
Wei Q; Ren X; Jiang Y; Jin H; Liu N; Li J
BMC Cardiovasc Disord; 2013 Mar; 13():13. PubMed ID: 23497312
[TBL] [Abstract][Full Text] [Related]
45. AGEs promote atherosclerosis by increasing LDL transcytosis across endothelial cells via RAGE/NF-κB/Caveolin-1 pathway.
Shu M; Cheng W; Jia X; Bai X; Zhao Y; Lu Y; Zhu L; Zhu Y; Wang L; Shu Y; Song Y; Jin S
Mol Med; 2023 Aug; 29(1):113. PubMed ID: 37605109
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis.
Ha CH; Kim S; Chung J; An SH; Park S; Choi D; Kwon K
Int J Mol Med; 2013 Aug; 32(2):373-80. PubMed ID: 23708564
[TBL] [Abstract][Full Text] [Related]
47. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
[TBL] [Abstract][Full Text] [Related]
48. Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts.
Lee TW; Kao YH; Lee TI; Chang CJ; Lien GS; Chen YJ
Int J Cardiol; 2014 May; 173(2):236-41. PubMed ID: 24630381
[TBL] [Abstract][Full Text] [Related]
49. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability.
Shai SY; Sukhanov S; Higashi Y; Vaughn C; Kelly J; Delafontaine P
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1916-24. PubMed ID: 20671230
[TBL] [Abstract][Full Text] [Related]
50. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse.
Ueno H; Koyama H; Shoji T; Monden M; Fukumoto S; Tanaka S; Otsuka Y; Mima Y; Morioka T; Mori K; Shioi A; Yamamoto H; Inaba M; Nishizawa Y
Atherosclerosis; 2010 Aug; 211(2):431-6. PubMed ID: 20435311
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.
Di Marco E; Gray SP; Chew P; Koulis C; Ziegler A; Szyndralewiez C; Touyz RM; Schmidt HH; Cooper ME; Slattery R; Jandeleit-Dahm KA
Diabetologia; 2014 Mar; 57(3):633-42. PubMed ID: 24292634
[TBL] [Abstract][Full Text] [Related]
52. Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice.
Zhao D; Tong L; Zhang L; Li H; Wan Y; Zhang T
Mol Med Rep; 2016 Dec; 14(6):4983-4990. PubMed ID: 27840935
[TBL] [Abstract][Full Text] [Related]
53. Panax notogingseng saponins suppress RAGE/MAPK signaling and NF-kappaB activation in apolipoprotein-E-deficient atherosclerosis-prone mice.
Dou L; Lu Y; Shen T; Huang X; Man Y; Wang S; Li J
Cell Physiol Biochem; 2012; 29(5-6):875-82. PubMed ID: 22613987
[TBL] [Abstract][Full Text] [Related]
54. Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes.
Hanssen NM; Brouwers O; Gijbels MJ; Wouters K; Wijnands E; Cleutjens JP; De Mey JG; Miyata T; Biessen EA; Stehouwer CD; Schalkwijk CG
Cardiovasc Res; 2014 Oct; 104(1):160-70. PubMed ID: 25139743
[TBL] [Abstract][Full Text] [Related]
55. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress.
Sima AV; Botez GM; Stancu CS; Manea A; Raicu M; Simionescu M
J Cell Mol Med; 2010 Dec; 14(12):2790-802. PubMed ID: 19818091
[TBL] [Abstract][Full Text] [Related]
56. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
57. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
58. The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice.
Lee D; Lee KH; Park H; Kim SH; Jin T; Cho S; Chung JH; Lim S; Park S
PLoS One; 2013; 8(8):e69669. PubMed ID: 23936343
[TBL] [Abstract][Full Text] [Related]
59. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice.
Shrikhande GV; Scali ST; da Silva CG; Damrauer SM; Csizmadia E; Putheti P; Matthey M; Arjoon R; Patel R; Siracuse JJ; Maccariello ER; Andersen ND; Monahan T; Peterson C; Essayagh S; Studer P; Guedes RP; Kocher O; Usheva A; Veves A; Kaczmarek E; Ferran C
PLoS One; 2010 Dec; 5(12):e14240. PubMed ID: 21151899
[TBL] [Abstract][Full Text] [Related]
60. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
